Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec;24(24):14639-14644.
doi: 10.1111/jcmm.16027. Epub 2020 Oct 27.

Contributions of PARP-1 rs1136410 C>T polymorphism to the development of cancer

Affiliations
Meta-Analysis

Contributions of PARP-1 rs1136410 C>T polymorphism to the development of cancer

Hunian Li et al. J Cell Mol Med. 2020 Dec.

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear chromatin-associated enzyme involved in the DNA damage response. SNP rs1136410 C>T, the most studied polymorphism in PARP-1 gene, is highly implicated in the susceptibility of cancer. However, the roles of PARP-1 rs1136410 C>T on cancer risk vary from different studies. We comprehensively screened all qualified publications from several databases, including PubMed, EMBASE, MEDLINE, CNKI and Wanfang. The searching was updated to April 2020. Our meta-analysis included 60 articles with 65 studies, comprised of a total of 23 996 cases with cancer and 33 015 controls. Overall, pooled data showed that the PARP-1 rs1136410 C>T polymorphism was significantly but a border-line associated with an increased risk of overall cancer (CC vs. TT/TC: OR = 1.11, 95% CI = 1.00-1.24; C vs T: OR = 1.07, 95% CI = 1.01-1.14). Subgroup analysis indicated that rs1136410 C allele contributed to high risk among gastric, thyroid, and cervical cancer, but lower risk among brain cancer. Furthermore, increased cancer risk was detected in the subgroups of Asian, controls from population-based design studies, and HWE ≤ 0.05 studies. Sensitivity analysis and Egger's test showed that results of the meta-analysis were fairly stable. The current study indicated that PARP1 rs1136410 C>T polymorphism may have an impact on certain types of cancer susceptibility.

Keywords: PARP1; cancer; meta-analysis; risk; rs1136410 C>T.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

FIGURE 1
FIGURE 1
Forest plot of studies evaluating pooled ORs of cancer risk under the dominant comparison model. Squares represent risk estimates of each study. The horizontal line represents study specific ORs and 95% CIs. The diamonds represent pooled estimates and 95%

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394‐424. - PubMed
    1. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer. 2004;90:747‐751. - PMC - PubMed
    1. Alves‐Lopes R, Touyz RM. PARP‐1 (Poly[ADP‐Ribose] Polymerase‐1). Hypertension. 2018;72:1087‐1089. - PMC - PubMed
    1. Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610‐621. - PMC - PubMed
    1. Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP‐ribose) polymerase, and DNA ligase III is a novel molecular 'nick‐sensor' in vitro. Nucleic Acids Res. 1996;24:4387‐4394. - PMC - PubMed

Publication types

Substances